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ABSTRACT
Background
New prophylactic and therapeutic strategies to combat human infections with highly
pathogenic avian influenza (HPAI) H5N1 viruses are needed. We generated neutralizing anti-
H5N1 human monoclonal antibodies (mAbs) and tested their efficacy for prophylaxis and
therapy in a murine model of infection.
Methods and Findings
Using Epstein-Barr virus we immortalized memory B cells from Vietnamese adults who had
recovered from infections with HPAI H5N1 viruses. Supernatants from B cell lines were screened
in a virus neutralization assay. B cell lines secreting neutralizing antibodies were cloned and the
mAbs purified. The cross-reactivity of these antibodies for different strains of H5N1 was tested
in vitro by neutralization assays, and their prophylactic and therapeutic efficacy in vivo was
tested in mice. In vitro, mAbs FLA3.14 and FLD20.19 neutralized both Clade I and Clade II H5N1
viruses, whilst FLA5.10 and FLD21.140 neutralized Clade I viruses only. In vivo, FLA3.14 and
FLA5.10 conferred protection from lethality in mice challenged with A/Vietnam/1203/04 (H5N1)
in a dose-dependent manner. mAb prophylaxis provided a statistically significant reduction in
pulmonary virus titer, reduced associated inflammation in the lungs, and restricted
extrapulmonary dissemination of the virus. Therapeutic doses of FLA3.14, FLA5.10, FLD20.19,
and FLD21.140 provided robust protection from lethality at least up to 72 h postinfection with
A/Vietnam/1203/04 (H5N1). mAbs FLA3.14, FLD21.140 and FLD20.19, but not FLA5.10, were
also therapeutically active in vivo against the Clade II virus A/Indonesia/5/2005 (H5N1).
Conclusions
These studies provide proof of concept that fully human mAbs with neutralizing activity can
be rapidly generated from the peripheral blood of convalescent patients and that these mAbs
are effective for the prevention and treatment of H5N1 infection in a mouse model. A panel of
neutralizing, cross-reactive mAbs might be useful for prophylaxis or adjunctive treatment of
human cases of H5N1 influenza.
The Editors’ Summary of this article follows the references.
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The continued circulation of highly pathogenic avian
inﬂuenza (HPAI) strains of subtype H5N1, and occasional
coincident cases of human infection (274 patients as of 19
February 2007, with 167 fatalities), has triggered international
public health concern. On the basis of haemagglutinin (HA)
sequences, these circulating HPAI H5N1 viruses fall into
different lineages, termed clades; viruses isolated in Viet Nam
and Indonesia in 2004 and 2005, respectively, were designated
as reference strains for Clades I and II [1]. The HA sequences
of Clade I and Clade II viruses differ by 4% to 5% at the
amino acid level and the viruses of the two clades are
antigenically distinguishable. The H5N1 viruses are not
efﬁciently transmitted from person to person. Potentially, a
virus capable of efﬁcient human-to-human transmission
could result from either adaptation of the HPAI H5N1
viruses and/or reassortment of the H5N1 virus genome with
that of a circulating human inﬂuenza virus. Widespread
dissemination of such a virus could cause signiﬁcant morbid-
ity and mortality, since humans are generally immunologi-
cally naı ¨ve to H5 inﬂuenza subtypes.
In humans, overall mortality in HPAI H5N1 infection
exceeds 60%, with variation according to the patient’s age
and the year of infection [2]. The basis for the apparent
virulence of HPAI H5N1 strains in humans is relatively poorly
understood. In Vietnamese patients, the disease was charac-
terized by severe pneumonia, lymphopenia, high viral loads in
the respiratory tract, and hypercytokinemia [3]. Beyond
supportive care, treatment options for human patients with
H5N1 avian inﬂuenza remain limited and are empiric; some
H5N1 viruses are resistant to older antiviral agents such as
amantadine and rimantadine [4,5], and the clinical efﬁcacy of
neuraminidase inhibitors such as oseltamavir and zanamavir
has not yet been conﬁrmed in prospective studies. In
addition, H5N1 viruses resistant to oseltamavir have been
reported [6,7]. Patients who recover from infection possess
antibodies that neutralize their infecting virus in vitro,
suggesting that antibody-mediated immunity may contribute
to resolution of infection [3].
Antibody-based therapy for human patients with H5N1 is a
hitherto unexplored, but potentially viable, treatment option.
Clinically, antibody therapy using polyclonal and monoclonal
antibodies (mAbs) is effectively used as prophylaxis against
varicella, hepatitis A, hepatitis B, rabies, and respiratory
syncytial virus infections [8]. In the context of inﬂuenza,
speciﬁc mAbs can confer prophylactic and therapeutic
protection in mice [9–11]. Passive immunization by vertical
acquisition of speciﬁc antibodies is also associated with
inﬂuenza immunity in animal models and in early infancy in
humans [12–15]. Of more immediate relevance, transfusion of
human blood products from patients recovering from the
1918 ‘‘Spanish ‘ﬂu’’ was associated with a 50% reduction in
inﬂuenza mortality during the pandemic [16]. Humanized
mouse mAbs and equine F(ab9)2 fragments speciﬁc for H5N1
have also been used for efﬁcacious prophylaxis and therapy
in the mouse model [17,18]. Collectively, these observations
suggest that passive antibody therapy against HPAI H5N1
viruses could be a potentially viable, adjunctive treatment
option in human cases of H5N1 inﬂuenza.
One approach to generating virus-speciﬁc neutralizing
mAbs is to use a highly efﬁcient method of Epstein-Barr
(EBV)-mediated immortalization of memory B cells from
convalescent individuals [19]. This approach is rapid and
yields stable B cell clones that secrete fully human antibodies
thathavebeenselectedinthecourseofanimmuneresponseto
thepathogen[19].Theaimofthisstudywastogeneratehuman
mAbs with neutralizing activity against H5N1 viruses. mAbs
were derived from immortalized memory B cells collected
from donors who had recovered from H5N1 infection. Four
mAbs, with neutralizing activity in vitro, had prophylactic and
therapeutic efﬁcacy in mice challenged with HPAI H5N1.
These mAbs, and others like them, could have a role in
adjunctive treatment of human cases of H5N1 inﬂuenza.
Materials and Methods
H5N1 Influenza Cases
The four adult blood donors in this study (CL26, CL36,
CL114, and CL115) were diagnosed with HPAI H5N1
infection between January 2004 and February 2005 at the
Hospital for Tropical Diseases in Ho Chi Minh City, Viet
Nam. Diagnosis of HPAI H5N1 inﬂuenza infection was made
by RT-PCR on respiratory specimens (from all four donors)
and culture of H5N1 inﬂuenza from respiratory specimens
(from donors CL26, CL36, and CL115) [20]. The clinical
features of acute disease in three of the four patients (donors
CL26, CL36, and CL115) have been described previously
(patients #5, #7, and #8 in the online supplement to [7]).
During early convalescence (1–4 mo post-illness onset), all
patients had detectable neutralizing antibody titers to their
autologous virus (median 96, range 32–200). The Scientiﬁc
and Ethical Committee of the Hospital for Tropical Diseases
and the Oxford University Tropical Research Ethical Com-
mittee approved the study protocol. All patients provided
written informed consent.
Influenza Viruses
GenBank accession numbers for the genomic sequences of
the H5N1 viruses isolated from subjects CL26 (A/Vietnam/
CL26/2004), CL36 (A/Vietnam/CL36/2004) and CL115 (A/
Vietnam/CL115/2005), have been published previously [3].
Strain A/chicken/Vietnam/VL1/2006 (H5N1) was isolated from
a cloacal swab of a chicken in southern Viet Nam in early
2006. The HPAI H5N1 reference viruses A/Vietnam/1203/
2004, A/Hong Kong/213/2003, A/Hong Kong/491/1997, A/
Vietnam/JPHN/30321/2005, and A/Indonesia/5/2005 were
kindly provided by Dr. Nancy Cox, Inﬂuenza Division,
Centers for Disease Control and Prevention, Atlanta, Geor-
gia, United States. Inﬂuenza A/California/7/2004 (H3N2) was
kindly provided by Dr. Roland Levandowski, CBER, Food and
Drug Administration, Bethesda, Maryland, United States.
Microneutralization Assays
Screening of supernatants from B cell lines and clones was
performed by microneutralization assay using MDCK cells
and 100 TCID50 (50% tissue culture infectious doses) of A/
Vietnam/1203/04 essentially as described previously [21].
Brieﬂy, neat supernatants were incubated with 100 TCID50
of virus for 1 h at room temperature prior to addition to
monolayers of MDCK cells. Cell monolayers were incubated
for a further 3–4 d and examined for cytopathic effect.
Determination of endpoint neutralizing antibody titers was
performed in a similar fashion, except that plasma or
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mixing with 100 TCID50 of virus. Plasma samples were tested
at a starting dilution of 1:10, while supernatants were tested
at a starting dilution of 1:8 and residual infectivity was tested
in four wells per dilution. The neutralizing titer was deﬁned
as the reciprocal of the highest dilution of serum at which the
infectivity of 100 TCID50 of the appropriate wild-type (wt)
H5N1 virus for MDCK cells was completely neutralized in
50% of the wells. Infectivity was identiﬁed by the presence of
cytopathic effect on d 4 and the titer was calculated by the
Reed-Muench method.
Immortalization of Memory B Cells and Selection of
Neutralizing Clones
Frozen peripheral blood mononuclear cells (PBMCs) were
thawed and stained with directly labeled antibodies to CD22
(Pharmingen, http://www.bdbiosciences.com/home) and to
immunoglobulin (Ig) M, IgD, and IgA (Jackson ImmunoR-
esearch, http://www.jacksonimmuno.com). CD22þIgM , IgD ,
IgA  B cells were isolated using a FACSAria (Becton Dick-
inson, http://www.bd.com) and immortalized at 30 B cells/well
in replicate cultures using EBV in the presence of CpG
oligodeoxynucleotide 2006 (Mycrosynth, http://www.
microsynth.ch) and irradiated allogeneic PBMC, as previously
described [19]. Cells were cultured in complete RPMI 1640
supplemented with 10% fetal calf serum (HyClone Labora-
tories, http://www.hyclone.com). Culture supernatants were
harvested after 14 days and assayed for neutralizing activity
against 100 TCID50 of inﬂuenza A/Vietnam/1203/04 (H5N1).
Cultures with measurable neutralizing activity were cloned at
0.5 cell/well in the presence of CpG 2006 and irradiated
PBMCs. B cell clones were cultured at a high cell density in
complete RPMI 1640 10% Ig-depleted fetal calf serum to
produce enriched supernatants containing 1–3 mg mAbs/ml.
MAbs were also puriﬁed on protein G columns (GE Health-
care Europe http://www.gehealthcare.com). The isotype, sub-
class, and light chain of the mAbs were characterized by
ELISA using speciﬁc antibodies and HRP-labeled anti-human
Ig antibody (Southern Biotechnology, http://www.
southernbiotech.com). Antibodies were quantiﬁed with refer-
ence to a standard certiﬁed preparation (Sigma-Aldrich,
http://www.sigmaaldrich.com).
MAbs for Prophylaxis and Therapy in Mice
Groups of 4–8 female BALB/c mice (4–6 wk old, mean
weight 18 g) were used in all experiments. Inoculation of mice
and tissue harvests were performed in a biosafety cabinet by
personnel wearing powered air purifying respirators. Inﬂu-
enza-infected animals were housed in a USDA and CDC
accredited biosafety level 3 (BSL3) animal facility in
accordance with protocols approved by the NIH Animal
Care and Use Committee. To measure prophylactic efﬁcacy,
mice were intraperitoneally (i.p.) injected with 1 ml of various
antibody preparations or hyperimmune sheep antisera raised
against baculovirus expressed HA of A/VN/1203/2004 (H5N1)
that was kindly provided by Dr. G. Kemble, Medimmune
Vaccines (http://www.medimmune.com). The H5N1 mAbs
FLA3.14, FLA5.10, FLD20.19 and FLD21.140 were adminis-
tered either as puriﬁed IgG or as enriched culture super-
natant. Control human antibodies were IgG1 mAbs D2.2 or
A146, speciﬁc for diphtheria toxin and anthrax protective
antigen, respectively, and were prepared in the same fashion
as the inﬂuenza-reactive antibodies. Twenty-four hours after
i.p. administration, the mice were bled to collect samples for
measurement of neutralizing human mAb titers, then
challenged intranasally (i.n.) with 10
5 TCID50 of A/Vietnam/
1203/04 (H5N1) or A/Indonesia/5/2005 (H5N1) in 50 ll. Mice
were observed and weighed daily before and after viral
infection. To determine viral titers following challenge, mice
were killed and the lungs, brains, and spleens were aseptically
removed. Tissues were homogenized in Leibovitz L-15
medium (Invitrogen, http://www.invitrogen.com) supple-
mented with antibiotic-antimycotic solution (Gibco, http://
www.invitrogen.com) to achieve suspensions of lung (10% w/
v), spleen (5% w/v), and brain (10% w/v), which were then
titrated on monolayers of MDCK cells in quadruplicate. The
viral titer was calculated by the Reed and Muench method
and expressed as log10 TCID50 per gram of tissue.
For therapy against A/Vietnam/1203/04 (H5N1), the mice
were ﬁrst infected i.n. with 5 LD50 of A/Vietnam/1203/04, then
24, 48, or 72 h later they were injected i.p. with 1 ml of a mAb
preparation. For therapy against A/Indonesia/5/2005 (H5N1),
mice were ﬁrst infected i.n. with 5 LD50 of A/Indonesia/5/2005
(H5N1), then 24 h later injected i.p. with 1 ml of a mAb
preparation.
Pathology
Mice were necropsied and the lungs were inﬂated with 10%
neutral buffered formalin and embedded in parafﬁn, and
sections were prepared. Slides were stained with hematoxylin
and eosin. For immunohistochemical demonstration of H5
antigen, parafﬁn sections were prepared and ABC immuno-
histochemistry was performed using a goat antibody to avian
inﬂuenza H5 Goat Alpha H5 (NIAID Reference Reagents, BEI
Resources, http://www.beiresources.org) diluted at 1:1,000,
with a Vector Rabbit Anti-Goat secondary antibody, the
Vector ABC Elite label (Vector Laboratories, http://www.
vectorlabs.com) diaminobenzidine as the chromogen, and
hematoxylin as the counterstain. Lung pathology was
evaluated in a semiquantitative manner by a pathologist
(JW) blind to the treatment.
Statistics
Kaplan-Meier survival curves and log rank tests were used
to measure differences between treatment arms in prophy-
lactically and therapeutically treated mice. The Mann-
Whitney U test was used to measure differences in viral loads
in mouse tissues. For statistical purposes, samples with
undetectable viral burdens were given the value 1.5 log10
TCID/g. All analyses were performed in Stata 8.2 software
(StataCorp, http://www.stata.com).
Results
Blood samples from four Vietnamese adults (CL26, CL36,
CL114, and CL115) who had recovered from HPAI H5N1
infection were collected 3–15 mo postinfection. IgG
þmemory
B cells recovered from frozen PBMC were immortalized with
EBV. Cultures secreting neutralizing antibodies were identi-
ﬁed by a microneutralization assay against the prototype
Clade I virus, A/Vietnam/1203/04 (H5N1), and cloned by
limiting dilution. Supernatants from approximately 11,000
wells were screened to identify 15 independent clones
secreting a neutralizing antibody. Of these clones, three were
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eleven from donor CL115. The number of clones isolated
from each donor did not correlate with the plasma titer of
neutralizing antibody, though this was not surprising given
the small sample size. Clones producing antibodies that
recognized H5 HA by ELISA, but did not neutralize live virus,
were also identiﬁed from each donor (unpublished data).
Clones FLA3.14 and FLA5.10, isolated from donor CL26, were
the ﬁrst obtained and were studied more extensively.
Subsequently, clones FLD20.19 and FLD21.140, isolated from
donor CL115, became available and were studied in parallel
with FLA3.14 and FLA5.10. Clones FLA3.14, FLA5.10,
FLD20.19, and FLD21.140 secreted IgG1,j antibodies with
neutralizing activity against the autologous virus A/Vietnam/
CL26/2004 and other more recent Clade I viruses circulating
in Viet Nam during 2005 and 2006 (Table 1). Signiﬁcantly,
more distant HPAI H5N1 strains, including the Clade II
H5N1 virus A/Indonesia/5/2005, were neutralized by FLA3.14
and FLD20.19 (Table 2). In contrast, none of these clones
neutralized an H3N2 inﬂuenza virus, A/California/7/2004
(Table 2). IgG1,j mAbs of irrelevant speciﬁcity (diphtheria
toxin and anthrax protective antigen) were used as negative
controls and did not neutralize any inﬂuenza virus (Tables 1
and 2). Thus, the mAbs selected for further study demon-
strated broad in vitro neutralizing activity against H5N1
viruses isolated from 1997 to 2005, albeit with some variation
in potency.
BALB/c mice are highly susceptible to infection with the
HPAI H5N1 viruses isolated in Asia in 1997 and since 2003.
Following i.n. administration, these H5N1 viruses replicate to
high titer in the lungs of the mice and some isolates
disseminate to extrapulmonary sites and are lethal for mice
[22,23]. To explore the efﬁcacy of mAbs FLA3.14 and FLA5.10
for pre-exposure prophylaxis, BALB/c mice were passively
immunized by i.p. administration of graded doses of mAbs
and then challenged i.n. with A/Vietnam/1203/04 (H5N1) 24 h
later. All preparations of mAb FLA5.10 conferred 100%
protection from lethality by A/Vietnam/1203/04 (p ¼ 0.001)
(Figure 1). mAb FLA3.14 also conferred some protection
from lethal A/Vietnam/1203/04 (H5N1) infection, but with
lower efﬁcacy and in a dose-dependent manner (Figure 1).
Mice receiving the highest dose of FLA3.14 were afforded
almost complete protection (p ¼ 0.001), whilst mice receiving
the lowest dose of FLA3.14 were as susceptible as mice that
received a human mAb of irrelevant speciﬁcity, though time
to death was delayed (p ¼ 0.02). Mice that received hyper-
immune anti-H5 polyclonal sheep antiserum were afforded
complete protection. These data, demonstrating the relatively
greater in vivo activity of FLA5.10 over FLA3.14 against A/
Vietnam/1203/04, are consistent with the in vitro neutraliza-
tion titers presented in Table 1.
Table 2. Neutralizing Titers of mAbs against Influenza A H3N2 and a Range of H5N1 Influenza Reference Viruses
Antibody Concentration Reciprocal Neutralizing Ab Titer against Indicated Influenza A Virus
H3N2 Strain H5N1 Strains
a
Cal/7/2004 HK/491/97 HK/213/03 VN/1203/04 JPHN/30321/05 Indo/5/05
Sheep antisera
b Not known ,10 2,032 2,560 806 1,613 806
FLA5.10 1 mg/ml ,10 127 4,064 508 806 ,10
FLA3.14 1 mg/ml ,10 403 508 226 508 508
FLD20.19 1 mg/ml ,10 905 5,120 1,613 6,451 5,120
FLD21.140 1 mg/ml ,10 32  14,882 5,120 12,902 ,10
A146
c 0.31 mg/ml ,10 ,10 ,10 ,10 ,10 ,10
Neutralization titers were recorded against 100 TCID50 of each strain
aInfluenza strains are described in full in Materials and Methods
bSheep antisera was raised to recombinant HA from Vietnam/1203/04 (H5N1)
cControl mAb of irrelevant specificity
doi:10.1371/journal.pmed.0040178.t002
Table 1. Neutralizing Titers of mAbs against Influenza A H5N1 Influenza Viruses Isolated from Viet Nam
Antibody Concentration Reciprocal Neutralizing Antibody Titer against Indicated Influenza A H5N1 Virus
a
VN/CL26/04 VN/115/05 VN/VL1/06
FLA5.10 0.7 mg/ml 2,958 107 1,782
FLA3.14 1.5 mg/ml 372 208 1,260
FLD20.19 1.5 mg/ml 1,280 4,012 2,460
FLD21.140 1.5 mg/ml 896 2,880 3,208
D2.2
b 0.7 mg/ml ,10 ,10 ,10
Neutralization titers were recorded against 100 TCID50 of each strain
aInfluenza strains are described in full in Materials and Methods
bControl mAb of irrelevant specificity
doi:10.1371/journal.pmed.0040178.t001
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FLA3.14 and FLA5.10 conferred protection from lethality,
the kinetics of viral infection in passively immunized mice
was deﬁned. Mice that were passively immunized with
FLA3.14, FLA5.10, or a human mAb of irrelevant speciﬁcity
(D2.2) were challenged with A/Vietnam/1203/04 (H5N1) 24 h
later, and the level of virus replication in different organs was
determined 2 and 4 d later. Mice that received the control
mAb, D2.2, had high titers of virus in the lungs (Figure 2A),
with evidence of extrapulmonary dissemination indicated by
viral replication in the brain (Figure 2B) and spleen (Figure
2C). In contrast, mice passively immunized with FLA3.14 or
FLA5.10 had signiﬁcantly (10- to 100-fold) lower titers of
virus in the lungs (Figure 2A) (p¼0.01, FLA3.14 versus D2.2; p
¼ 0.001, FLA5.10 versus D2.2), undetectable viral burdens in
the brain (Figure 2B) and a low titer of virus detected in the
spleens of mice that received FLA5.10 (Figure 2C). Alongside
the reduction in lung viral titers, mice that received
prophylaxis with FLA5.10 had less dramatic pathological
changes in the pulmonary airways and parenchymal tissue
(Figure 3). Thus, the percentage of abnormal bronchioles with
necrosis and viral antigen in lung sections from mice (n ¼ 2
per group) that received FLA5.10 prophylaxis was less (13%)
than in control mice (80%). Similarly, there were fewer
inﬂammatory interstitial lesions in which H5 antigen was
detected by immunohistochemical staining in the lung
sections of mice given FLA5.10 relative to the control
antibody, D2.2 (1 versus .10) (Figure 3). To a slightly lesser
extent, FLA3.14 prophylaxis also limited bronchiolitis (31%
versus 80%) and H5-associated interstitial pathology (2 versus
.10) when compared with control mice (n ¼ 2). These data
suggest that prophylaxis with FLA3.14 or FLA5.10 probably
confers protection from lethal challenge through a combi-
nation of limiting viral replication in the lung, attenuating
virus-induced lung pathology, and blocking extrapulmonary
dissemination of virus to distant organs.
Attenuation of established infection represents a clinically
relevant endpoint for antiviral therapy against H5N1 infec-
tion. To this end, the efﬁcacy of treatment with FLA3.14,
FLA5.10, FLD20.19, and FLD21.140 was determined in BALB/c
mice i.n. infected 24, 48, or 72 h previously with 5 LD50 of A/
Vietnam/1203/04 (H5N1). FLA3.14, FLA5.10, FLD20.19, and
FLD21.140 provided robust protection from lethality in A/
Vietnam/1203/04 (H5N1) infected mice at all time points,
whilst an irrelevant control mAb, D2.2, gave no protection (p¼
0.003) (Figure 4). These promising therapeutic results against
a Clade I virus from Viet Nam led us to examine the
therapeutic efﬁcacy of mAbs FLA3.14, FLA5.10, FLD20.19,
and FLD21.140 against A/Indonesia/5/2005, an antigenically
divergent H5N1 virus from Clade II. The efﬁcacy of treatment
with FLA3.14, FLA5.10, FLD20.19, and FLD21.140 was
determined in BALB/c mice infected i.n. 24 h previously with
5L D 50 of A/Indonesia/5/2005. Consistent with the in vitro
neutralization data (Table 2), mice treated with FLA3.14 and
FLD20.19, but not FLA5.10 or the control mAb D2,2, were
Figure 1. Passive Immunization and Survival after Challenge with A/
Vietnam/1203/04 (H5N1)
BALB/c mice (n¼5 per group) were passively immunized by i.p. injection
of graded doses of anti-H5N1 mAbs FLA3.14 or FLA5.10, the control
mAbs D2.2 or A146, or hyperimmune sheep antisera specific for the
H5N1 HA protein. Mice were challenged i.n. with 50 ll of A/Vietnam/
1203/04 (10
5 TCID50/mouse) 24 h later. The data show the Kaplan-Meier
survival curves for the 2 wk period of observation. Mice that received
either sheep anti-H5 antisera or FLA5.10 were completely protected from
lethal infection (sheep antisera or FLA5.10 versus D2.2, p¼0.001, log rank
test). FLA3.14 afforded significant protection at 20 mg/kg and 10 mg/kg
(FLA3.14 versus D2.2, p ¼ 0.001, log rank test). The lowest dose of
FLA3.14 (1 mg/kg) delayed time to death (FLA3.14 versus D2.2, p¼0.02,
log rank test), but did not prevent fatal infection.
doi:10.1371/journal.pmed.0040178.g001 Figure 2. Pulmonary Virus Titers and Extrapulmonary Dissemination of
A/Vienam/1203/04 (H5N1) Following Passive Immunization
The data depict the mean (6 interquartile range) viral titer in (A) lungs,
(B) brain, and (C) spleen of groups of five BALB/c mice passively
immunized by i.p. injection of mAbs FLA3.14, FLA5.10, or the control
mAb D2.2, then challenged i.n. with 50 ll of A/Vietnam/1203/04 (10
5
TCID50/mouse) 24 h later. On days 2 and 4 there was significantly less
virus recovered in splenic and pulmonary tissue of mice that had
received either FLA3.14 or FLA5.10 than mice that had received the
control mAb, D2.2. (* p , 0.01 versus D2.2; ** p , 0.001 versus D2.2). The
lower limit of detection (1.5 log10 TCID50/g) is shown by the arrow.
doi:10.1371/journal.pmed.0040178.g002
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tion (p ¼ 0.003) (Figure 5). Although FLD21.140 did not
demonstrate neutralizing activity in vitro against A/Indonesia/
5/2005 (Table 2), treatment with this mAb signiﬁcantly
protected the mice (p¼0.003) from A/Indonesia/5/2005 lethal
infection. This observation of neutralization in vivo suggests
that a factor found in vivo enhances the neutralizing activity
of this mAb, accounting for its efﬁcacy in vivo in preventing
mortality associated with infection. These data provide proof
of concept that mAb therapy for at least 72 h postinfection in
the mouse model can markedly improve survival from highly
virulent H5N1 infection. Importantly, these data also imply it
is possible to obtain signiﬁcant cross-protection against a
Clade II H5N1 virus using a mAb elicited by a Clade I virus.
Figure 3. Histopathology in Pulmonary Tissue of Passively Immunized and Challenged Mice
(A) Hematoxylin and eosin-stained lung sections (403) revealed diffuse interstitial pneumonia (I) and bronchial and bronchiolar (Br) involvement in a
mouse infected with influenza A/VN/1203/04 (H5N1) after i.p. injection of the control mAb D2.2.
(B) Mouse given mAb FLA5.10 prior to infection with influenza A/VN/1203/04 (H5N1), showing much less lung involvement than in (A).
(C) Immunohistochemistry (403) revealed H5 antigen in bronchi, bronchioles (Br), and interstitial lesions (I) in a mouse given influenza A/VN/1203/04
(H5N1) following i.p. injection of the control mAb D2.2.
(D) H5 antigen in bronchus (Br) and not in bronchioles or interstitial areas (I) in a mouse given mAb FLA5.10 prior to influenza challenge.
(E) High magnification (1003) of (C) showing abundant H5 antigen in interstitial alveolar lesions (I) and bronchiolar epithelium (Br).
(F) High magnification of (D) (1003) showing H5 antigen only focally in a bronchus (Br) and not in the interstitial alveolar areas (I).
doi:10.1371/journal.pmed.0040178.g003
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The risk of a devastating human inﬂuenza pandemic caused
by an H5N1 inﬂuenza strain remains difﬁcult to quantify.
What is clear is that zoonotic infections with HPAI H5N1
viruses continue to occur in Southeast Asia with a mortality
in 2006 of 67% and for which there are few speciﬁc
interventions [20,24]. Here we report on the generation of
four fully human mAbs with a spectrum of neutralizing
activity against multiple strains of HPAI H5N1 viruses in vitro
and in vivo. These mAbs could have potential in the
adjunctive treatment of human pandemic or zoonotic
H5N1 cases.
Prophylaxis with mAb FLA5.10, and to a lesser extent
FLA3.14, conferred signiﬁcant immunity to mice infected
with A/Vietnam/1203/04. Passive immunity was associated
with signiﬁcantly reduced viral burdens in the lung and
negligible dissemination of virus to the brain or spleen. Viral
dissemination might be an important aspect in the patho-
genesis of H5N1 viruses in both mice and humans. In
Vietnamese patients with H5N1 infection, fatal outcomes
were strongly associated with the presence of viral genetic
material, or viable virus, at extrapulmonary sites [3].
Conversely, there was no evidence of extrapulmonary virus
dissemination in patients who survived [3]. In addition to
evidence of viral dissemination, patients with fatal H5N1
infections had high viral loads in the respiratory tract,
hypercytokinemia, multiple organ dysfunction, and acute
respiratory distress syndrome [3]. Our proposed model of
H5N1 pathogenesis [3] argues that early diagnosis and
antiviral interventions that limit the ensuing inﬂammatory
cascade should be central to treatment.
Although not a new strategy, antibody-based therapy for
severe inﬂuenza caused by H 5 N 1v i r u s e sr e p r e s e n t sa
plausible intervention. Multiple reports of physicians using
human blood products from recovering inﬂuenza patients
appeared during the 1918 Spanish H1N1 inﬂuenza pandemic.
A recent review of these studies suggested this treatment was
associated with a halving in mortality (37% to 16%), and that
early treatment was associated with greater beneﬁts [16]. The
assumption underlying these observations is that neutralizing
antiviral antibodies in the plasma preparations modulated
the course of viral infection and thereby prevented the
development of acute respiratory distress syndrome and
other complications [16]. These same tenets form the ration-
ale for therapy using the mAbs generated in this study, with
the potential of a scaleable therapeutic product free of
adventitious agents. The strengths of the approach for human
mAb generation described here are: (1) it uses the human
immune response rather than that of animal surrogates—the
antibodies selected will be those that have been generated in
response to the natural infectious pathogen and have
protected the individual, (2) it is fast, (3) screening can be
performed using functional assays, i.e., neutralization, (4) it
allows screening of a large repertoire of antibodies to select
those with the most favorable proﬁle (potency and breadth of
reactivity), and (5) since the antibodies are of human origin
the risks of self-reactivity against self-antigens is minimized
when compared with antibodies generated in mice or
through phage display.
The mAbs produced in this study were derived from
Figure 4. mAb Therapy and Survival in Mice with Established A/Vietnam/
1203/04 (H5N1) Infection
The data show the Kaplan-Meier survival curves for groups of BALB/c
mice (n¼5 per group) that were infected i.n. with 5 LD50 of A/Vietnam/
1203/04, then 24, 48, or 72 h later treated by i.p. injection with the
control mAb D2.2, or the anti-H5N1 mAbs FLA3.14, FLA5.10, FLD20.19, or
FLD21.140, each at 50 mg/kg body weight. Postinfection therapy at 24,
48, or 72 h with mAbs FLA3.14, FLA5.10, FLD20.19, or FLD21.140 was
associated with significant protection from lethal infection at all time
points (FLA3.14, FLA5.10, FLD20.19, or FLD21.140 versus D2.2, p¼0.003,
log rank test).
doi:10.1371/journal.pmed.0040178.g004
Figure 5. mAb Therapy and Survival in Mice with Established A/
Indonesia/5/2005 (H5N1) Infection
The data show the Kaplan-Meier survival curves for groups of BALB/c
mice (n¼5 per group) that were infected i.n. with 5 LD50 of A/Indonesia/
5/2005 (H5N1) then 24 h later treated by i.p. injection with the control
mAb D2.2, or the anti-H5N1 mAbs FLA3.14, FLA5.10, FLD20.19, or
FLD21.140, each at 50 mg/kg body weight. Postinfection therapy at 24 h
with mAbs FLA3.14, FLD20.19, or FLD21.140, but not FLA5.10 or D2.2,
was associated with absolute protection from lethal infection (FLA3.14,
FLD21.140 or FLD20.19 versus D2.2, p ¼ 0.003, log rank test).
doi:10.1371/journal.pmed.0040178.g005
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from H5N1 infection. Overall, compared with the yield of
neutralizing B cell clones we previously derived from patients
who had recovered from SARS coronavirus infection [19],
donor-derived B cell clones that neutralized H5N1 inﬂuenza
were relatively scarce. These observations might reﬂect the
weak immunogenicity of the H5 HA, as suggested in trials of
inactivated H5N1 vaccines in human volunteers [25].
Two of the four mAbs characterised in this study had cross-
reactive antiviral activity in vitro and in vivo against Clade I
and Clade II H5N1 viruses. This is signiﬁcant, as it suggests
the presence of conserved neutralizing epitopes on repre-
sentatives of these two clades. One mAb (FLD21.140) was
effective in neutralizing a Clade II virus in vivo but not in
vitro, suggesting the neutralizing activity of this mAb is
dependent upon a factor found in vivo, such as complement.
Similar ﬁndings have been previously reported by Gerhard
and colleagues who identiﬁed a mouse mAb against an
inﬂuenza A H1 HA that had neutralizing activity in vivo but
not in vitro [26,27]. The in vitro neutralizing activity of this
mAb was enhanced by the C1q component of the comple-
ment system plus another undeﬁned serum factor [26,27].
It was possible to employ the human mAbs generated in
this study as potent therapeutic agents for at least 72 h after
A/Vietnam/1203/04 infection. This is important as most
zoonotic cases of human H5N1 infection do not present to
health care facilities until at least several days after illness
onset [3]. Potentially, a cocktail of these cross-reactive mAbs
could represent an adjunctive treatment option against H5N1
infection. The dose of mAb required for effective anti-
inﬂuenza H5N1 activity in a patient is uncertain, though we
note that the only mAb licensed for use against a viral agent
(respiratory syncytial virus) is used at 15 mg/kg of body
weight.
The ongoing process of antigenic variation in antibody
binding sites, called antigenic drift, in inﬂuenza viruses
represents a challenge to vaccine design and also to therapy
using mAbs. Although the molecular targets of the neutraliz-
ing mAbs in this study have not been determined, they are
presumed to reside around the highly variable receptor
binding region of HA1 [28–30] and that differences in
potency are related to epitope speciﬁcity and overall avidity.
To date, we have not identiﬁed mAb epitope escape mutants
of H5N1. These issues, and the mechanism of virus
neutralization, are subjects of ongoing virological and
crystallographic studies.
HPAI H5N1 viruses continue to circulate and evolve in bird
populations. It is not certain that a pandemic virus originat-
ing from an HPAI H5N1 virus will resemble the H5N1 viruses
studied here, or that the mAbs generated here will have
neutralizing activity against a pandemic virus. Nevertheless,
we are encouraged by the broad neutralizing activity of these
antibodies in vitro, and the moderate doses required in vivo
to confer protection. Ultimately, we hope that these mAbs,
and others like them, could constitute a cocktail of cross-
reactive, neutralizing antibodies that could be employed as
adjunctive treatment of H5N1 inﬂuenza.
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Editors’ Summary
Background. Every year, millions of people catch influenza, a viral
disease of the nose, throat, and airways. Although most recover,
influenza outbreaks (epidemics) kill about half a million people annually.
Epidemics occur because small but frequent changes in the viral proteins
(antigens) to which the immune system responds mean that an immune
response produced one year provides only partial protection against
influenza the next year. Human flu viruses also occasionally appear that
contain major antigenic changes. People have little or no immunity to
such viruses (which often originate in animals or birds), so these viruses
can start deadly pandemics—global epidemics. The Spanish flu
pandemic in 1918/9, Asian flu in 1957, and Hong Kong flu in 1968 all
killed millions. Experts believe that another pandemic is overdue and
may be triggered by the avian H5N1 influenza virus—the name indicates
that this bird virus carries type 5 hemagglutinin and type 1
neuraminidase, the two major flu antigens. H5N1, which rapidly kills
infected birds, is now present in flocks around the world and, since 1997,
it has caused 258 cases of human flu and 153 deaths. People have
caught H5N1 through close contact with infected birds but, luckily, H5N1
rarely passes between people.
Why Was This Study Done? H5N1 might acquire the ability to move
between people and start a human influenza pandemic at any time.
Some of the H5N1 viruses are resistant to the antiviral drugs used to treat
flu and there will inevitably be a lag of some months between the
emergence of a human pandemic H5N1 strain and the bulk production
of a vaccine effective against it. Thus, new preventative and therapeutic
strategies are needed to combat human infections with H5N1. One
possibility is passive immunotherapy—treating people with antibodies
(proteins that recognize antigens) that can stop H5N1 from infecting
cells (so-called neutralizing antibodies). In this study, the researchers
have generated neutralizing human monoclonal antibodies (laboratory-
produced preparations that contain one type of human antibody) and
tested their ability to halt viral growth in mice infected with H5N1.
What Did the Researchers Do and Find? Patients who have survived
infection with H5N1 make neutralizing antibodies, so the researchers
isolated and immortalized the immune cells making these antibodies
from the patients’ blood. They grew up each cell separately and purified
the antibody that the cells made. These monoclonal antibodies were
then tested for their ability to neutralize H5N1 and other flu viruses in the
laboratory. The researchers identified several that neutralized the H5N1
strain with which the patients were originally infected and chose two for
further study. In the test tube, the four antibodies neutralized closely
related H5N1 viruses and an H5N1 virus from a different lineage (clade)
that has also caused human disease, in addition to the original H5N1
virus, although with different efficacies. In mice, the antibodies provided
protection from infection with the original virus when given a day before
or one to three days after infection. Three antibodies also partly
protected the mice against H5N1 from a different clade. Finally, the
researchers showed that the antibodies protected mice by limiting viral
replication, by lessening the deleterious effects of the virus in the lungs,
and by stopping viral spread out of the lungs.
What Do These Findings Mean? These results indicate that passive
immunotherapy with human monoclonal antibodies could help to
combat avian H5N1 if (or when) it starts a human pandemic. Passive
immunotherapy is already used to prevent infections with several other
viruses. In addition, a crude form of the approach—early treatment of
patients with plasma (the liquid portion of blood) from convalescent
patients—halved the death rate during the Spanish flu pandemic. Large
amounts of pure monoclonal antibodies can be relatively easily made for
clinical use, and this study indicates that some monoclonal antibodies
neutralize H5N1 viruses from different clades. The researchers sound a
note of caution, however: Before passive immunotherapy can help to
halt an H5N1 pandemic, they warn, the monoclonal antibodies will have
to be tested to see whether they can neutralize not only all the currently
circulating H5N1 viruses but also any emerging pandemic versions,
which might be antigenically distinct.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040178.
  US Centers for Disease Control and Prevention information about
influenza for patients and professionals including key facts about avian
influenza
  US National Institute of Allergy and Infectious Disease feature on
seasonal, avian, and pandemic flu
  World Health Organization factsheet on influenza and information on
avian influenza, including latest figures for confirmed human cases
  UK Health Protection Agency information on seasonal, avian, and
pandemic influenza
  Wikipedia pages on passive immunity and monoclonal antibodies
(note: Wikipedia is an online encyclopedia that anyone can edit)
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